Vanderbilt’s Peter Embí to Lead National Library of Medicine
Embí will oversee the world’s largest biomedical library and shepherd the investment of its approximately $495 million annual budget.
Read More
Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder
Ultragenyx Pharmaceuticals’ apazunersen did not meet the goals of its Phase 3 test in Angelman syndrome, a rare genetic neurological disorder with no FDA-approved therapies. The disappointing result has some readthrough to Ionis Pharmaceuticals and Oak Hill Bio, each in clinical development with Angelman drugs designed to work in a similar way as Ultragenyx’s failed…
Rural Transformation Plans Bolster Community Paramedicine Programs
States seek to expand EMS programs that do at-home visits that can help prevent readmissions through disease-specific assessments, chronic disease management, patient education, and medication reconciliation
Healing Through Heritage: Why Culturally Grounded Recovery Matters on Tribal Lands
This shift is not about replacing clinical care with tradition. It is about recognizing that healing in Native communities has always been deeply connected to culture. The post Healing Through Heritage: Why Culturally Grounded Recovery Matters on Tribal Lands appeared first on MedCity News.
This Device Could Prevent Lung Biopsy’s Most Common — and Costly — Complication
Selio Medical developed an FDA-cleared hydrogel device that seals CT-guided lung biopsy punctures before they can cause pneumothorax — a collapsed lung complication that affects up to a third of the 800,000+ such biopsies performed annually in the U.S. The post This Device Could Prevent Lung Biopsy’s Most Common — and Costly — Complication appeared…
Thyme Care Raises $125M, Launches New Oncology Parent Entity
Thyme Care’s Series E round was led by Morgan Health and included participation from Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health. The post Thyme Care Raises $125M, Launches New Oncology Parent Entity appeared first on MedCity News.
Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial
In a mid-stage study, Teva’s drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge — eating food with gluten to see if it prompts an immune response. There are currently no FDA-approved drugs for celiac disease, but Teva’s antibody is part of a competitive race to bring patients the first one….
Automation Didn’t Dehumanize Care. Bad Systems Did.
[Sponsored] We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring. The post Automation Didn’t Dehumanize Care. Bad Systems Did. appeared first on MedCity News.
The Healthcare Inflection Point: AI Can’t Fix 1990s Technology
Isolated improvements rarely translate into enterprise-wide transformation when they are layered onto outdated, inefficient workflows instead of being integrated into redesigned care delivery. The post The Healthcare Inflection Point: AI Can’t Fix 1990s Technology appeared first on MedCity News.
The Pandemic Risk of “What I’ve Never Seen Before”
By MIKE MAGEE The world of medical science largely closed ranks last month in defense of Tony Fauci. Dr. Fauci had been hauled before the Senate Homeland Security Committee to face hostile entrapment by long time critique Senator Rand Paul of Kentucky. Taking no chances, his lawyers had the former head of NIH’s Infectious Disease…